Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources

European Lung Cancer Congress 2024

20 - 23 Mar 2024

Prague, Czech Republic

ELCC-2024-1000x1000

Presentations (slides) and webcasts are available to ESMO Members and registered delegates according to the presenters' agreement to release them. 
Abstracts and ePosters are open access.

The copyright protected educational resources from this event are for personal usage only and not to be shared with any third parties. ESMO thanks the authors for their generosity.

Meeting programme Next/upcoming meetings
Review the current state-of-the-art in lung cancer therapy, update your knowledge in prevention, screening, detection and much more.

The European Lung Cancer Congress 2024 provides insights into the prevention, diagnosis, biology and multi-disciplinary management of thoracic malignancies. Learning objectives included updating knowledge in early detection, reviewing current state-of-the-art systemic management, the emerging contribution of precision medicine, genomics technologies and artificial intelligence.

Abstracts, slides, webcasts and ePosters are published!

ESMO Colloquium supported by Eli Lilly & Company
Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations

Slides and Webcasts

Industry partners' Satellite Symposia

Watch the webcasts

Hide
Filter by:
ESMO Colloquium
Search:
Reset

There are 6 resources available

Welcome and introduction

Presenter: Zofia Piotrowska

Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations

Resources:

Webcast

Q&A and discussion

Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations

Resources:

Webcast

Concluding remarks

Presenter: Antonio Calles Blanco

Session: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.